Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2016

01-07-2016 | Review

Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?

Authors: K. A. Nyrop, G. R. Williams, H. B. Muss, S. S. Shachar

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Abstract

Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9–17 %), stable weight (47–64 %), and gained weight (27–36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.
Literature
1.
Dixon JK, Moritz DA, Baker FL (1978) Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum 5(3):5–7PubMed
2.
Knobf MK, Mullen JC, Xistris D, Moritz DA (1983) Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum 10(2):28–33PubMed
3.
Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd NF (1985) Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5(2):195–200PubMedCrossRef
4.
Vance V, Mourtzakis M, McCargar L, Hanning R (2011) Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 12(4):282–294PubMedCrossRef
5.
Fedele P, Orlando L, Schiavone P et al (2014) BMI variation increases recurrence risk in women with early-stage breast cancer. Future Oncol 10(15):2459–2468PubMedCrossRef
6.
Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH (2013) Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 24(10):2506–2514PubMedPubMedCentralCrossRef
7.
Nechuta S, Chen WY, Cai H et al (2016) A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. Int J Cancer 138(9):2088–2097PubMedCrossRef
8.
Sinicrope FA, Dannenberg AJ (2011) Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol 29(1):4–7PubMedCrossRef
9.
Bradshaw PT, Ibrahim JG, Stevens J, Cleveland RJ, Abrahamson PE et al (2012) Postdiagnosis change in bodyweight and survival after breast cancer diagnosis. Epidemiology 23(2):320–327PubMedPubMedCentralCrossRef
10.
Chan DS, Vieira AR, Aune D et al (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914PubMedPubMedCentralCrossRef
11.
Protani M, Coory M, Martin JH (2010) Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 123:627–635PubMedCrossRef
12.
Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML (2015) Weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 107(12):djv275PubMedCrossRef
13.
Caan BJ, Emond JA, Su HI et al (2012) Effect of postdiagnosis weight change on hot flash status among early-stage breast cancer survivors. J Clin Oncol 30(13):1492–1497PubMedPubMedCentralCrossRef
14.
Young A, Weltzien E, Kwan M, Castillo A, Caan B, Kroenke CH (2014) Pre- to post-diagnosis weight change and associations with physical functional limitations in breast cancer survivors. J Cancer Surviv 8(4):539–547PubMedPubMedCentralCrossRef
15.
Forsythe LP, Alfano CM, George SM et al (2013) Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior. Breast Cancer Res Treat 137(2):617–630PubMedCrossRef
16.
Befort CA, Austin H, Klemp JR (2011) Weight control needs and experiences among rural breast cancer survivors. Psychooncology 20(10):1069–1075PubMedCrossRef
17.
Voskuil DW, van Nes JG, Junggeburt JM, van de Velde CJ, van Leeuwen FE, de Haes JC (2010) Maintenance of physical activity and body weight in relation to subsequent quality of life in postmenopausal breast cancer patients. Ann Oncol 21(10):2094–2101PubMedCrossRef
18.
Schmitz KH, Neuhouser ML, Agurs-Collins T et al (2013) Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst 105(18):1344–1354PubMedPubMedCentralCrossRef
19.
Keegan TH, Kurian AW, Gali K et al (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105(5):938–946PubMedPubMedCentralCrossRef
20.
Kroenke CH, Michael YL, Shu XO, Poole EM (2016) Post-diagnosis social networks, and lifestyle and treatment factors in the After Breast Cancer Pooling Project. Psychooncology. doi:10.​1002/​pon.​4059 PubMed
21.
Makari-Judson G, Braun B, Jerry DJ, Mertens WC (2014) Weight gain following breast cancer diagnosis: implication and proposed mechanisms. World J Clin Onc. 5(3):272–282CrossRef
22.
Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527–518
23.
24.
Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 15(10):1899–1905PubMedCrossRef
25.
Benz CC (2008) Impact of aging on the biology of breast cancer. Crit Rev Oncog Hematol 66(1):65–74CrossRef
26.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ et al (2015) Breast cancer, version 1.2016. J Natl Compr Canc Netw 13(12):1475–1485PubMed
27.
Taylor WC, Muss HB (2010) Recent advances: adjuvant therapy for older women with breast cancer. Cancer J 16(4):289–293PubMedCrossRef
28.
Eisen A, Fletcher GG, Gandhi S et al (2015) Optimal systemic therapy for early breast cancer in women: a clinical practice guideline. Curr Oncol 22(Suppl 1):S67–S81PubMedPubMedCentral
29.
Burstein HJ, Griggs JJ, Prestrud AA, Temin S (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 6(5):243–246
30.
Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97(17):1262–1271PubMedCrossRef
31.
Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816PubMedCentralPubMedCrossRef
32.
Sestak I, Harvie M, Howell A, Forbes JF, Dowsett M, Cuzick J (2012) Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat 134(2):727–734PubMedCrossRef
33.
Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917PubMedCrossRef
34.
Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedCrossRef
35.
Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067PubMedPubMedCentralCrossRef
36.
Whelan TJ, Goss PE, Ingle JN et al (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28):6931–6940PubMedCrossRef
37.
van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331PubMedCrossRef
38.
Caan BJ, Kwan ML, Hartzell G, Castillo A, Slattery ML et al (2008) Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19(10):1319–1328PubMedPubMedCentralCrossRef
39.
Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. 132(2):1107–1118
40.
Gallicchio L, MacDonald R, Wood B, Rushovich E, Helzlsouer KJ (2012) Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy. Climacteric 15(4):339–349PubMedCrossRef
41.
Su HI, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211PubMedPubMedCentralCrossRef
42.
Zivian MT, Salgado B (2008) Side effects revisited: women’s experiences with aromatase inhibitors. Breast Cancer Action, San Francisco
43.
Oberguggenberger A, Hubalek M, Sztankay M, Meraner V, Beer B et al (2011) Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat 128(2):553–561PubMedCrossRef
44.
Garreau JR, DeLaMelena T, Walts D, Karamlou K, Johnson N (2006) Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 192:496–498PubMedCrossRef
45.
Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57CrossRef
46.
Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast. 13(5):363–368PubMedCrossRef
47.
Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K (2015) Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer. Cancer Epi Biomarkers Prev 24(8):1262–1269CrossRef
48.
Mortimer J, Behrendt CE (2013) Severe menopausal symptoms are widespread among survivors of breast cancer treatment regardless of time since diagnosis. J Palliat Med 16(9):1130–1134PubMedCrossRef
49.
Sedjo RL, Hines LM, Byers T et al (2013) Long-term weight gain among Hispanic and non-Hispanic White women with and without breast cancer. Nutr Cancer 65(1):34–42PubMedCrossRef
50.
Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer–effect of tamoxifen. Breast Cancer Res Treat 22(2):129–132PubMedCrossRef
51.
Gu K, Chen X, Zheng Y et al (2010) Weight change patterns among breast cancer survivors: results from the Shanghai breast cancer survival study. Cancer Causes Control 21(4):621–629PubMedCrossRef
52.
Saquib N, Flatt SW, Natarajan L, Thomson CA, Bardwell WA et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the Women’s healthy Eating and Living (WHEL) study. Breast Cancer Res Treat 105(2):177–186PubMedCrossRef
53.
Francini G, Petrioli R, Montagnani A et al (2006) Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 95(2):153–158PubMedPubMedCentralCrossRef
54.
Sedjo R, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. Cancer Surv 8(3):410–418CrossRef
55.
Reddy S, Sadim M, Li J et al (2013) Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer. Br J Cancer 109(4):872–881PubMedPubMedCentralCrossRef
56.
Han HS, Lee KW, Kim JH et al (2009) Weight changes after adjuvant treatment in Korean women with early breast cancer. Breast Cancer Res Treat 114(1):147–153PubMedCrossRef
57.
Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J et al (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17(1):120–129PubMed
58.
Makari-Judson G, Judson CH, Mertens WC (2007) Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year. Breast 13(3):258–265CrossRef
59.
60.
Irwin ML, McTiernan A, Baumgartner RN, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782PubMedPubMedCentralCrossRef
61.
Kumar NB, Allen K, Cantor A et al (1997) Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat 44(2):135–143PubMedCrossRef
62.
Malinovszky KM, Cameron D, Douglas S et al (2004) Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). Breast 13(5):363–368PubMedCrossRef
63.
Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88(21):1529–1542PubMedCrossRef
64.
Su H, Sammel MD, Springer E, Freeman EW, DeMichele A, Mao JJ (2010) Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors. Breast Cancer Res Treat 124(1):205–211PubMedPubMedCentralCrossRef
65.
Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 8(6):49–57CrossRef
66.
McGowan P, Perry M, Hewett J, Ge B, Sanfilippo K (2006) Weight gain in breast cancer patients: tamoxifen versus anastrozole. J Clin Oncol 24(18S (June 20 Suppl)):10544
67.
Lin CJ, DeRoo LA, Jacobs SR, Sandler DP (2012) Accuracy and reliability of self-reported weight and height in the Sister Study. Public health Nutr 15(6):989–999PubMedCrossRef
68.
Weaver TW, Kushi LH, McGovern PG et al (1996) Validation study of self-reported measures of fat distribution. Int J Obes Relat Metab Disord 20(7):644–650PubMed
69.
Gillum RF, Sempos CT (2005) Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J 4:27PubMedPubMedCentralCrossRef
70.
Lim U, Wilkens LR, Albright CL, Novotny R, Le Marchand L, Kolonel LN (2013) University of Hawai’i Cancer Center Connection: bias in self-reported anthropometry in relation to adiposity and adulthood weight gain among postmenopausal Caucasian and Japanese American Women. Hawai’i J Med Public Health 72(12):445–449
71.
Bradshaw PT, Nichols HB, Caan BJ (2016) RE: weight gain after breast cancer diagnosis and all-cause mortality: systematic review and meta-analysis. J Natl Cancer Inst 108(4):djw023PubMedCrossRef
72.
Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD et al (2009) Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev 18(5):1403–1409PubMedPubMedCentralCrossRef
73.
Heideman WH, Russell NS, Gundy C, Rookus MA, Voskuil DW (2009) The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45:119–126PubMedCrossRef
74.
Crew KD, Greenlee H, Capodice J et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883PubMedCrossRef
75.
Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CHG, van Laarhoven HWM (2013) Arthralgia during aromatase inhibitor treatment in early breast cancer. Cancer Nurs 1–8
76.
Brown JC, Mao JJ, Stricker C, Hwang WT, Tan KS, Schmitz KH (2014) Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivors. Breast J 20(1):22–28PubMedCrossRef
77.
Kim SH, Cho YU, Kim SJ (2013) Weight gain and its correlates among breast cancer survivors. Asian Nurs Res 7(4):161–167CrossRef
78.
DeSantis CE, Lin CC, Mariotto AB et al (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4):252–257PubMedCrossRef
79.
Colleoni M, Gelber S, Goldhirsch A et al (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13–93. J Clin Oncol 24(9):1332–1341PubMedCrossRef
80.
Fallowfield LJ, Bliss JM, Porter L et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24(6):910–917PubMedCrossRef
81.
Fallowfield LJ, Kilburn LS, Langridge C et al (2012) Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 106(6):1062–1067PubMedPubMedCentralCrossRef
82.
van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377(9762):321–331PubMedCrossRef
83.
Ganz PA, Cecchini RS, Julian TB et al (2016) Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet 387(10027):857–865PubMedCrossRef
84.
Lorizio W, Wu AH, Beattie MS et al (2012) Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 132(3):1107–1118PubMedCrossRef
85.
Glaus A, Boehme C, Thürlimann B et al (2006) Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol 17(5):801–806PubMedCrossRef
86.
McInnes J, Knobf MT (2001) Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nurs Forum 28(4):675–684PubMed
87.
Love RR, Hutson PR, Havighurst TC, Cleary JF (2005) Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clin Cancer Res 11(4):1500–1503PubMedCrossRef
88.
Sedjo RL, Byers T, Ganz PA et al (2014) Weight gain prior to entry into a weight-loss intervention study among overweight and obese breast cancer survivors. J Cancer Surviv 8(3):410–418PubMedPubMedCentralCrossRef
89.
Basaran G, Turhal NS, Cabuk D et al (2011) Weight gain after adjuvant chemotherapy in patients with early breast cancer in Istanbul Turkey. Med Oncol 28(2):409–415PubMedCrossRef
90.
Vagenas D, DiSipio T, Battistutta D et al (2015) Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study. BMC Cancer 15(1):28 (Epub ahead of print) PubMedPubMedCentralCrossRef
Metadata
Title
Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence?
Authors
K. A. Nyrop
G. R. Williams
H. B. Muss
S. S. Shachar
Publication date
01-07-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3874-0

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue

Brief Report

Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment

Epidemiology

Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer

Review

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications

Epidemiology

Impact of a prior diagnosis of DCIS on survival from invasive breast cancer

Epidemiology

Axillary evaluation and lymphedema in women with ductal carcinoma in situ

Clinical trial

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits